About the Company
Harvard Bioscience is a global developer, manufacturer and marketer of life sciences equipment to support research and drug discovery. It is traded on NASDAQ under the stock symbol HBIO. Headquartered in Holliston, Massachusetts, United States, the company has 20 wholly owned subsidiaries. Brands include: AHN Biotechnologie, Biochrom, BioDrop, BTX, CMA, Coulbourn Instruments, Harvard Apparatus, HEKA, Hoefer, Hugo Sachs Elektronik, Multichannel Systems, Panlab, Scie-Plas, and Warner Instruments. Its CEO is James Green. The company has approximately 500 employees, with 300 of those in the USA, and five principal manufacturing facilities in New Brighton, Minnesota, Holliston, Massachusetts, Reutlingen, Germany, Barcelona, Spain, and March, Germany.
Sector
Industrial Applications and Services
Industry
Laboratory Analytical Instruments
Employees
168
Exchange
Nasdaq
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $HBIO News
Harvard Bioscience Announces Action to Improve Operational Efficiency and Support Ongoing Investments in Growth
HOLLISTON, Mass., April 09, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: HBIO) today announced a labor force reduction to improve its ...
HBIO Harvard Bioscience, Inc.
Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services for life science applications in the United States and internationally. The company offers cellular ...
Harvard Bioscience to implement $4M in layoffs
Holliston-based biotech company Harvard Bioscience is undergoing a labor force reduction in an attempt to shore up its ...
Harvard Bioscience, Inc. (NASDAQ:HBIO) Q4 2023 Earnings Call Transcript
Harvard Bioscience, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good morning, and thank you for standing by.
Is There An Opportunity With Harvard Bioscience, Inc.'s (NASDAQ:HBIO) 34% Undervaluation?
The projected fair value for Harvard Bioscience is US$6.70 based ... it might be 34% undervalued How far off is Harvard Bioscience, Inc. (NASDAQ:HBIO) from its intrinsic value?
Harvard Bioscience to Showcase Latest Solutions for Preclinical and Organoid Applications at Society of Toxicology Meeting
HOLLISTON, Mass., March 06, 2024 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) today announced that it will be showcasing its latest product innovations at the Society of Toxicology ...
Harvard Bioscience: Q4 Earnings Snapshot
HOLLISTON, Mass. (AP) — HOLLISTON, Mass. (AP) — Harvard Bioscience Inc. (HBIO) on Thursday reported a loss of $1.8 million in its fourth quarter. The Holliston, Massachusetts-based company ...
Harvard Bioscience Inc.
Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International stock ...
Harvard Bioscience, Inc.: Harvard Bioscience Announces Action to Improve Operational Efficiency and Support Ongoing Investments in Growth
Harvard Bioscience, Inc. (Nasdaq: HBIO) today announced a labor force reduction to improve its operating cost structure and support its ongoing investments ...
Harvard Bioscience Inc HBIO
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...
Harvard Bioscience Inc HBIO
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Loading the latest forecasts...